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Rectal Microbicides 101 
 
What are rectal microbicides?   
 
 Currently in development, a rectal microbicide (RM) is an agent that could be 
formulated as a lubricant, gel, douche, or an enema and used rectally to reduce a 
person’s risk of HIV infection. Rectal microbicides could offer both primary protection in 
the absence of condoms and back-up protection if a condom breaks or slips off during 
anal intercourse (AI). Vaginal microbicides are also being studied. 
 
 For those unable or unwilling to use condoms, RMs could be a safe and effective 
alternative way of reducing risk, especially if they enhanced sexual pleasure and were 
unobtrusive enough to motivate consistent use.  
 
 Such alternatives are essential if we are to address the full spectrum of prevalent sexual 
practices and the basic human need for accessible, user-controlled HIV and STI (sexually 
transmitted infection) prevention tools.  
 
Why do we need rectal microbicides? 
 
 At the end of 2008, UNAIDS 
estimated that 33.4 million people 
were living with HIV/AIDS 
worldwide, and that 2.7 million 
people were newly infected that 
year.  
 
 Because an act of unprotected anal 
intercourse (AI) is 10 to 20 times 
more likely to result in HIV infection 
compared to unprotected vaginal 
intercourse, and because AI is a 
common human behaviour – in 
both men and women – it is likely 
that unprotected AI is a significant 





 While condoms are an effective 
barrier to HIV transmission during 
AI, many people do not use them 
due to a number of issues including 
power dynamics in sexual 
relationships, stigma, and a serious 
lack of availability.  According to the 
Global HIV Prevention Working 
Group, only 9% of individuals at risk 
for HIV infection had access to 
condoms in 2008.  We need better 





We need more tools in 
the prevention toolbox. 
 
  
Who needs rectal microbicides?   
 
 Anal intercourse (AI) is a common human sexual behaviour, practiced by heterosexual 
men and women, gay men, and other men 
who have sex with men (MSM).  
 
 Approximately 5 –10% of the world’s 
general population engages in AI.  
 
 Among women with multiple risk 
behaviours for HIV acquisition, an 
estimated 30 –50% engage in AI.  
 
 Gay men and other MSM are 19 times more likely to be infected with HIV compared to 
the world’s general population – in both developed and developing countries. Most of 






What is happening in research and development? 
 
 The field of rectal microbicide (RM) research is more vibrant than ever.  
 Researchers are developing and testing products in laboratory tests and animal 
studies.  
 Safety trials look to see if the RM does not cause harm and is well tolerated. One 
safety trial has been completed, and other safety trials have begun. Once candidate 
RMs are shown to be safe, they can move into efficacy trials to determine if they 
actually work to prevent HIV infection.  
 Acceptability and behavioural studies help determine the characteristics of products 
people would most likely use, and determine who is engaging in AI. 
 Baseline studies investigate what normally happens physiologically during AI. 
 Formulation studies explore how different chemicals and substances would be put 
together to create a safe and effective RM. 
 Distribution studies ask the question - where do RMs need to go in the human body? 
 Lubricant safety studies seek to establish whether currently available lubricants are safe 
to use rectally. The lubricants being tested are not designed to specifically block the 
transmission of HIV, but it is important to know whether they are causing any harm. 
 
To learn more about the current RM research and the development pipeline in detail, as well as 
related scientific activities, read IRMA’s report, From Promise to Product: Advancing Rectal 
Microbicide Research and Advocacy, available on the IRMA website – 
www.rectalmicrobicides.org. 
 
Most anal intercourse around 
the world is unprotected. 
 What are the field’s challenges? 
 
There are significant biological, socio-cultural and political issues surrounding the research and 
development of safe, effective and acceptable RMs. A great deal of denial, stigma and shame 
surround the act of AI, hampering efforts to collect accurate sexual behavioural data. And 
adequate funding is lacking. 
 
There was U.S. $7.2 million spent 
globally on RM research in 2010. 
Annual investments must increase 
by 40% from 2011-2014 and must 
increase six-fold in the years 2015-
2020 to ensure a minimum of 
candidate products enter late-
stage testing for effectiveness in 
humans. 
 
In consultation with leading 
researchers in the field, IRMA 
calculated these approximate annual funding needs for RM research and development over the 
next 10 years based on a number of assumptions regarding future activities. One assumption 
was that the field would move forward rectal microbicides based on antiretroviral (ARV) 
products, combination ARV products, and non-ARV products.  See Section 3 of From Promise to 
Product: Advancing Rectal Microbicide Research and Advocacy to learn more about these 
estimates and assumptions. 
 
 Here’s the bottom line.  
 
Any RM must be safe and effective. It must also be 
acceptable, readily available and easy to use for all people 
who engage in AI.  Unprotected AI is a significant driver of new HIV infections among gay men 
and other MSM, and likely plays a large role in the epidemic among heterosexuals. Partners of 
all genders need and deserve prevention methods beyond condoms. We need choices.  
 
 
Who is IRMA? 
 
International Rectal Microbicide Advocates (IRMA) is a global network of advocates, scientists, 
policy makers and funders from six continents working together to advance a robust RM 
research and development agenda. IRMA is based in the United States with chapters in Latin 
America and Nigeria. 
 
Get involved and learn more.  Visit www.rectalmicrobicides.org.   
 
 
[This fact sheet was prepared in May 2010.] 
 
Now is the time 
for rectal 
microbicides. 
